Alliqua’s (ALQA) Buy Rating Reiterated at HC Wainwright
Alliqua Inc. (NASDAQ:ALQA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Friday.
A number of other analysts have also recently commented on the stock. Chardan Capital restated a “buy” rating on shares of Alliqua in a report on Sunday, July 10th. Zacks Investment Research upgraded shares of Alliqua from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Alliqua has an average rating of “Buy” and an average target price of $2.50.
Shares of Alliqua (NASDAQ:ALQA) traded down 1.12% during mid-day trading on Friday, hitting $0.88. 98,395 shares of the stock traded hands. Alliqua has a 1-year low of $0.70 and a 1-year high of $3.82. The company’s 50-day moving average price is $0.91 and its 200 day moving average price is $1.00. The company’s market capitalization is $26.11 million.
Alliqua (NASDAQ:ALQA) last released its quarterly earnings results on Tuesday, August 9th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.32. The business had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $5.38 million. Alliqua had a negative net margin of 73.41% and a negative return on equity of 53.07%. Equities research analysts forecast that Alliqua will post ($0.72) EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of ALQA. Renaissance Technologies LLC raised its position in Alliqua by 589.0% in the first quarter. Renaissance Technologies LLC now owns 137,800 shares of the company’s stock valued at $113,000 after buying an additional 117,800 shares in the last quarter. Suffolk Capital Management LLC raised its position in Alliqua by 18.0% in the second quarter. Suffolk Capital Management LLC now owns 1,206,127 shares of the company’s stock valued at $1,351,000 after buying an additional 184,274 shares in the last quarter. Vanguard Group Inc. raised its position in Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares in the last quarter. Finally, US Bancorp DE raised its position in Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock valued at $204,000 after buying an additional 41,732 shares in the last quarter. 29.89% of the stock is owned by hedge funds and other institutional investors.
Alliqua Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Stock Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related stocks with our FREE daily email newsletter.